---
title: "Policy dividends continue to be released, and the pharmaceutical retail industry welcomes new opportunities for transformation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275955803.md"
description: "Recently, the policy dividends in the pharmaceutical retail industry have been continuously released, and the pace of transformation and integration upgrades has accelerated. The Ministry of Commerce and eight other departments jointly issued the \"Opinions on Promoting the High-Quality Development of the Pharmaceutical Retail Industry,\" introducing support measures to promote the transformation and upgrading of the industry. Industry insiders stated that policy guidance, market clearing, and model innovation are advancing simultaneously, and the pharmaceutical retail industry has entered a new stage of structural optimization and increased concentration, with leading enterprises that have scale advantages set to benefit significantly"
datetime: "2026-02-14T00:17:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275955803.md)
  - [en](https://longbridge.com/en/news/275955803.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275955803.md)
generator: "portal-rs"
---

# Policy dividends continue to be released, and the pharmaceutical retail industry welcomes new opportunities for transformation

Recently, the policy dividends in the pharmaceutical retail industry have been continuously released, and the pace of transformation and integration upgrades is accelerating. The Ministry of Commerce and eight other departments recently jointly issued the "Opinions on Promoting the High-Quality Development of the Pharmaceutical Retail Industry," introducing a series of support measures focusing on industry integration, prescription outflow, commercial insurance, and more, to promote the transformation and upgrading of the pharmaceutical retail industry. Industry insiders indicate that with the simultaneous advancement of policy guidance, market clearing, and model innovation, China's pharmaceutical retail industry is entering a new stage of structural optimization, increased concentration, and reconstruction of profit models, where leading enterprises with scale advantages and integration capabilities will significantly benefit. (China Securities Journal)

### Related Stocks

- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [603939.CN](https://longbridge.com/en/quote/603939.CN.md)
- [002727.CN](https://longbridge.com/en/quote/002727.CN.md)
- [601607.CN](https://longbridge.com/en/quote/601607.CN.md)
- [600511.CN](https://longbridge.com/en/quote/600511.CN.md)
- [159938.CN](https://longbridge.com/en/quote/159938.CN.md)
- [603233.CN](https://longbridge.com/en/quote/603233.CN.md)
- [000028.CN](https://longbridge.com/en/quote/000028.CN.md)
- [603883.CN](https://longbridge.com/en/quote/603883.CN.md)

## Related News & Research

- [Shanghai Pharmaceuticals Finalizes Participation in Shanghai Biomedical Phase II Fund](https://longbridge.com/en/news/293755364.md)
- [Shanghai Pharmaceuticals Joins RMB Biomedical Fund in Connected Transaction](https://longbridge.com/en/news/293039667.md)
- [Shanghai Pharmaceuticals AGM Secures Strong Shareholder Backing and Governance Stability](https://longbridge.com/en/news/290840513.md)
- [China's Humanoid Robot Products Exceed 400 Models, Accounting for Over Half of Global Total](https://longbridge.com/en/news/293168438.md)
- [China's 1H25 Innovative Drug Out-Licensing Deal Value Exceeds USD100 Billion, Hitting New High](https://longbridge.com/en/news/293168428.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**